OMass Therapeutics
OMass Therapeutics is a biotech & life sciences company based in Oxford, GB, founded in 2016. It has raised $308.22 million in disclosed funding. Its latest round was a Series C of €275 million in October 2026.
Overview
No overview yet. It is written from sources once there are enough of them.
Funding
Total disclosed: $308.2M across 1 round. Computed only from sourced rounds.
| Date | Company | Amount | Stage | Lead | Other investors | Sector | Sources |
|---|---|---|---|---|---|---|---|
| €275M | Series C | Bain Capital Life Sciences, Forbion, Novo Holdings | Janus Henderson Investors +9 | Biotech & Life Sciences | 1 |
- OMass Therapeutics€275M
Led by Bain Capital Life Sciences, Forbion, Novo Holdings · with Janus Henderson Investors, +9
Investors
Questions and answers
How much has OMass Therapeutics raised?
OMass Therapeutics has raised $308.22 million in disclosed funding across 1 round tracked by OSH.
Who has invested in OMass Therapeutics?
Investors in OMass Therapeutics include Bain Capital Life Sciences, Forbion, Novo Holdings, Janus Henderson Investors, SV Health Investors and 8 more.
When and where was OMass Therapeutics founded?
OMass Therapeutics was founded in 2016 and is based in Oxford, GB.
Timeline
Founded
Sources
- 1.Oxford spin-out OMass Therapeutics lands €275 million to bring novel small-molecule therapies closer to patients — EU-Startups, Oct 16, 2026